Home
Services
Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassay Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
Polymers & Contract Manufacturing
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services
Products
Small Molecule Inhibitors and Antagonist
Bioactive Compounds and Agonist
Primary Antibodies
Catalog Peptides
Amino Acids Derivatives
Reagents
Fluorescent dyes
Intermediates
PCR
Proteasomes and Enzymes
Enzyme substrate
Nucleotides
Promotions
Customer Support
About Us
Site Map
Contact Us
Small Molecule Inhibitors and Antagonist
Anti-virus
Cell Cycle
DMPK/Tox
Endocrinology
Epigenetics
GPCR/G-protein
Mitogen-activated Protein Kinases (MAPK)
PI3K/Akt/mTOR
Proteases/Proteasome
Protein Tyrosine Kinases (PTK)
Stem Cells
TGF-Beta/Smad
Transporter
Others
Cat. No. Name Size Price Add Cart
KI0461Oseltamivir Phosphate250 mg$194

Chemical Characteristic

Product NameOseltamivir Phosphate
SynonymsTamiflu, EEC-Ro 64-0796
CAS No.204255-11-8
Molecular Weight 410.4
FormulaC16H31N2O8P
Chemical Name(3R,?4R,?5S)?-?4-?(acetylamino)?-?5-?amino-?3-?(1-?ethylpropoxy)?-?-?cyclohexene-?1-?carboxylic acid ethyl ester, phosphate (1:1)
SmilesC1(=C[C@H]([C@@H]([C@H](C1)N)NC(=O)C)OC(CC)CC)C(=O)OCC
Chemical Structure

Biological activities

Oseltamivir carboxylate is a potent but specific influenza neuraminidase inhibitor that blocks replication of a wide variety of influenza A and B viruses in vitro. Oseltamivir phosphate is the ethyl ester prodrug of oseltamivir carboxylate. The inhibition constant (Ki) for oseltamivir carboxylate against mutant 274Y is significantly elevated compared with wild type 274H. The Ki is 200 and 0.5 nM, respectively. [1] Oseltamivir carboxylate inhibits wild-type and mutant viruses with IC50 of 100 nM and 100 μM, respectively. Oseltamivir inhibits wild-type and mutant (R292K) neuraminidase with Ki of 0.13 nM and 3.6 μM. The ratio of Ki for mutant and wild type neuraminidase is 2.8 ? 104. Oseltamivir carboxylate is the most susceptible against human isolate A/Thailand/1(Kan-1)/04 (H5N1) and avian isolate A/duck/Laos/25/06 (H5N1) with mean IC50 of 0.3 and 0.1 nM, respectively. In contrast, human isolate A/Turkey/65-1242/06 (H5N1) is the least susceptible with a mean IC50 of 10.8 nM. Oseltamivir against A/chicken/Jogjakarta/BBVET/IX/04 virus had the greatest protection (100% survival; maximum weight change, -11.2%) while oseltamivir protects 80% of animals infected with the human A/Thailand/1(Kan-1)/04 virus. Oseltamivir against A/whooper swan/Mongolia/244/05 and A/duck/Laos/25/06 influenza viruses is less effective by 70 and 60% survival, respectively.[2] In vivo, oseltamivir generates antiviral effect against VN1203/04 in a dose-dependent manner. Eight-day regimens ameliorates oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day markedly decreases virus titers in organs and provided 60% and 80% survival rates, respectively.[3] Oseltamivir carboxylate is secreted via an organic anion pathway, but oseltamivir carboxylate does not inhibit amoxicillin renal secretion. [4]

Protocols

Oseltamivir is dissolved in terile phosphate-buffered saline.[2]

References

[1] Ives JA, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002, 55(2): 307-317.
[2] Carr J, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002, 54(2): 79-88.
[3] Yen HL, et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005, 192(4): 665-672.
[4] Hill G,et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002, 30(1): 13-19.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.
About
KareBayTM Biochem
Sitemap
Blog
Custom Services
Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services
Biochemical Products
Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR
Contact Us
KareBayTM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852
Telephone
: 732-823-1545

Fax
: 732-823-1349
product@karebaybio.com
service@karebaybio.com
support@karebaybio.com
Follow Us
Follow Karebay on LinkedinFollow IMAGING on Twitter Google+ Facebook